(Q45128593)

9 December 2017

title

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer (English)

1 reference

9 December 2017

5

1 reference

9 December 2017

1

Anthony V D'Amico

1 reference

9 December 2017

4

Marian Loffredo

1 reference

9 December 2017

Ming-Hui Chen

2

1 reference

9 December 2017

Andrew A Renshaw

series ordinal

3

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

9 December 2017

1 reference

9 December 2017

volume

113

1 reference

9 December 2017

issue

12

1 reference

9 December 2017

page(s)

3290-3297

1 reference

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Prognostic importance of comorbidity in a hospital-based cancer registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Modelling competing risks in cancer studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23970

7 January 2021

Identifiers

DOI

10.1002/CNCR.23970

1 reference

release_ao2ik7mi6bhbrlcwnuvkgtrjby

9 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ao2ik7mi6bhbrlcwnuvkgtrjby

24 November 2022

mapped directly with Wikidata item

1 reference